{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:12:06Z","timestamp":1765278726298,"version":"3.46.0"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method for intraabdominal cavity chemotherapy. It combines the benefits of a minimally invasive approach (low morbidity and easy to repeat) with the pharmacokinetic advantages of intraperitoneal administration and tolerance seems excellent. We would like to report one case of a serious adverse event, acute respiratory distress syndrome, which is likely related to oxaliplatin administration; all signs disappeared within a few days.<\/jats:p>","DOI":"10.1515\/pp-2021-0126","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T01:37:48Z","timestamp":1633397868000},"page":"167-170","source":"Crossref","is-referenced-by-count":3,"title":["Acute respiratory distress syndrome (ARDS) after pressurized intraperitoneal aerosol chemotherapy with oxaliplatin: a case report"],"prefix":"10.1515","volume":"6","author":[{"given":"Emilie","family":"Thibaudeau","sequence":"first","affiliation":[{"name":"Department of Oncological Surgery , Institut de Canc\u00e9rologie de l\u2019Ouest , Saint-Herblain , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Brianchon","sequence":"additional","affiliation":[{"name":"Department of Anesthesia , Institut de Canc\u00e9rologie de l\u2019Ouest , Saint-Herblain , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Raoul","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology , Institut de Canc\u00e9rologie de l\u2019Ouest , Saint-Herblain , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Dumont","sequence":"additional","affiliation":[{"name":"Department of Oncological Surgery , Institut de Canc\u00e9rologie de l\u2019Ouest , Saint-Herblain , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"2025120909295127620_j_pp-2021-0126_ref_001","doi-asserted-by":"crossref","unstructured":"Franko, J, Shi, Q, Meyers, JP, Maughan, TS, Adams, RA, Seymour, MT, et al.. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol 2016;17:1709\u201319. https:\/\/doi.org\/10.1016\/s1470-2045(16)30500-9.","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"2025120909295127620_j_pp-2021-0126_ref_002","doi-asserted-by":"crossref","unstructured":"Esquis, P, Consolo, D, Magnin, G, Pointaire, P, Moretto, P, Ynsa, MD, et al.. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg 2006;244:106\u201312. https:\/\/doi.org\/10.1097\/01.sla.0000218089.61635.5f.","DOI":"10.1097\/01.sla.0000218089.61635.5f"},{"key":"2025120909295127620_j_pp-2021-0126_ref_003","doi-asserted-by":"crossref","unstructured":"Solass, W, Hetzel, A, Nadiradze, G, Sagynaliev, E, Reymond, MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 2012;26:1849\u201355. https:\/\/doi.org\/10.1007\/s00464-012-2148-0.","DOI":"10.1007\/s00464-012-2148-0"},{"key":"2025120909295127620_j_pp-2021-0126_ref_004","doi-asserted-by":"crossref","unstructured":"Alyami, M, Hubner, M, Grass, F, Bakrin, N, Villeneuve, L, Laplace, N, et al.. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 2019;20:e368\u201377. https:\/\/doi.org\/10.1016\/s1470-2045(19)30318-3.","DOI":"10.1016\/S1470-2045(19)30318-3"},{"key":"2025120909295127620_j_pp-2021-0126_ref_005","doi-asserted-by":"crossref","unstructured":"Demtroder, C, Solass, W, Zieren, J, Strumberg, D, Giger-Pabst, U, Reymond, MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis 2016;18:364\u201371. https:\/\/doi.org\/10.1111\/codi.13130.","DOI":"10.1111\/codi.13130"},{"key":"2025120909295127620_j_pp-2021-0126_ref_006","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Pfeiffer, P, Lundell, L, Mortensen, MB. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey. Clin Exp Metastasis 2018;35:103\u20138. https:\/\/doi.org\/10.1007\/s10585-018-9895-9.","DOI":"10.1007\/s10585-018-9895-9"},{"key":"2025120909295127620_j_pp-2021-0126_ref_007","doi-asserted-by":"crossref","unstructured":"Ranieri, VM, Rubenfeld, GD, Thompson, BT, Ferguson, ND, Caldwell, E, Fan, E, et al.. Acute respiratory distress syndrome: the Berlin definition. J Am Med Assoc 2012;307:2526\u201333. https:\/\/doi.org\/10.1001\/jama.2012.5669.","DOI":"10.1001\/jama.2012.5669"},{"key":"2025120909295127620_j_pp-2021-0126_ref_008","doi-asserted-by":"crossref","unstructured":"Teixeira Farinha, H, Grass, F, Labgaa, I, Pache, B, Demartines, N, H\u00fcbner, M. Inflammatory response and toxicity after pressurized intraperitoneal aerosol chemotherapy. J Canc 2018;9:13\u201320. https:\/\/doi.org\/10.7150\/jca.21460.","DOI":"10.7150\/jca.21460"},{"key":"2025120909295127620_j_pp-2021-0126_ref_009","doi-asserted-by":"crossref","unstructured":"Dumont, F, Passot, C, Raoul, JL, Kepenekian, V, Leli\u00e8vre, B, Boisdron-Celle, M, et al.. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. Eur J Canc 2020;140:37\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.010.","DOI":"10.1016\/j.ejca.2020.09.010"},{"key":"2025120909295127620_j_pp-2021-0126_ref_010","doi-asserted-by":"crossref","unstructured":"Giger-Pabst, U, Bucur, P, Roger, S, Falkenstein, TA, Tabchouri, N, Le Pape, A, et al.. Comparison of tissue and blood concentrations of oxaliplatin administrated by different modalities of intraperitoneal chemotherapy. Ann Surg Oncol 2019;26:4445\u201351. https:\/\/doi.org\/10.1245\/s10434-019-07695-z.","DOI":"10.1245\/s10434-019-07695-z"},{"key":"2025120909295127620_j_pp-2021-0126_ref_011","doi-asserted-by":"crossref","unstructured":"Lurvink, RJ, Tajzai, R, Rovers, KP, Wassenaar, ECE, Moes, DJAR, Pluimakers, G, et al.. Systemic pharmacokinetics of oxaliplatin after intraperitoneal administration by electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC) in patients with unresectable colorectal peritoneal metastases in the CRC-PIPAC trial. Ann Surg Oncol 2021;28:265\u201372. https:\/\/doi.org\/10.1245\/s10434-020-08743-9.","DOI":"10.1245\/s10434-020-08743-9"},{"key":"2025120909295127620_j_pp-2021-0126_ref_012","doi-asserted-by":"crossref","unstructured":"Siebert, M, Alyami, M, Mercier, F, Gallice, C, Villeneuve, L, B\u00e9rard, F, et al.. Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report. Canc Chemother Pharmacol 2019;83:425\u201330. https:\/\/doi.org\/10.1007\/s00280-018-3740-3.","DOI":"10.1007\/s00280-018-3740-3"},{"key":"2025120909295127620_j_pp-2021-0126_ref_013","doi-asserted-by":"crossref","unstructured":"Garrido, M, O\u2019Brien, A, Gonzalez, S, Clavero, JM, Orellana, E. Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. Chest 2007;132:1997\u20139. https:\/\/doi.org\/10.1378\/chest.07-0536.","DOI":"10.1378\/chest.07-0536"},{"key":"2025120909295127620_j_pp-2021-0126_ref_014","doi-asserted-by":"crossref","unstructured":"Gagnadoux, F, Roiron, C, Carrie, E, Monnier-Cholley, L, Lebeau, B. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol 2002;25:388\u201390. https:\/\/doi.org\/10.1097\/00000421-200208000-00014.","DOI":"10.1097\/00000421-200208000-00014"},{"key":"2025120909295127620_j_pp-2021-0126_ref_015","doi-asserted-by":"crossref","unstructured":"De Weerdt, A, Dendooven, A, Snoeckx, A, Pen, J, Lammens, M, Jorens, PG. Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient. BMC Canc 2017;17:586. https:\/\/doi.org\/10.1186\/s12885-017-3576-y.","DOI":"10.1186\/s12885-017-3576-y"},{"key":"2025120909295127620_j_pp-2021-0126_ref_016","doi-asserted-by":"crossref","unstructured":"Suthar, KH, Al Mutar, S, Venkatesan, R. Oxaliplatin-induced pulmonary toxicity: a rare but serious complication. Cureus 2020;12:e7483. https:\/\/doi.org\/10.7759\/cureus.7483.","DOI":"10.7759\/cureus.7483"},{"key":"2025120909295127620_j_pp-2021-0126_ref_017","doi-asserted-by":"crossref","unstructured":"Dumont, F, Senellart, H, Pein, F, Campion, L, Glehen, O, Goere, D, et al.. Phase I\/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): rationale and design. Pleura Peritoneum 2018;3:20180120. https:\/\/doi.org\/10.1515\/pp-2018-0120.","DOI":"10.1515\/pp-2018-0120"},{"key":"2025120909295127620_j_pp-2021-0126_ref_018","doi-asserted-by":"crossref","unstructured":"Shen, Y, Li, C, Liu, W, Mao, W, Qian, H, Wang, H, et al.. Clinical analysis of hypersensitivity reactions to oxaliplatin among colorectal cancer patients. Oncol Res 2018;26:801\u20137. https:\/\/doi.org\/10.3727\/096504017x15139039328978.","DOI":"10.3727\/096504017X15139039328978"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0126\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:06:39Z","timestamp":1765278399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0126\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12,20]]},"published-print":{"date-parts":[[2021,12,20]]}},"alternative-id":["10.1515\/pp-2021-0126"],"URL":"https:\/\/doi.org\/10.1515\/pp-2021-0126","relation":{},"ISSN":["2364-768X"],"issn-type":[{"type":"electronic","value":"2364-768X"}],"subject":[],"published":{"date-parts":[[2021,10,5]]}}}